Survodutide
Survodutide is an experimental weekly weight-loss injection from Boehringer Ingelheim and Zealand Pharma. It has finished several Phase 3 trials but, as of November 2026, is not approved for any use.
- Legal lane: investigational. Not approved in any country.
- Evidence grade: B
- Form: weekly injection under the skin
- Also studied in: fatty liver disease (MASH)
What it is
Survodutide activates two receptors, GLP-1 and glucagon, the same pairing as mazdutide. The glucagon side is meant to increase fat burning in the liver, which is why it is also being tested in liver disease.
What the evidence shows
- SYNCHRONIZE-1 (New England Journal of Medicine, 2026): 725 adults with obesity and no diabetes, treated for 76 weeks. Average weight loss was 12.2% on 3.6 mg and 13.0% on 6.0 mg, against 5.4% on placebo. Among people who stayed on the 6.0 mg dose, it was 16.6%.
- SYNCHRONIZE-2: in 752 adults with type 2 diabetes, the 6.0 mg dose produced 9.8% weight loss against 3.9% on placebo.
- SYNCHRONIZE-CVOT (The Lancet, November 2026): met its goal of showing no increase in heart and stroke risk.
These are large, well-run trials. The grade is B because the drug is not approved and its weight loss is smaller than the approved tirzepatide in separate trials.
Dosing used in the trials
There is no approved dose. Trials gave survodutide once a week and raised the dose gradually to a maintenance dose of 3.6 mg or 6.0 mg. The dose-raising period is where most side effects and dropouts happened, and newer trials use slower, more flexible schedules.
Side effects
- Stomach and gut side effects were very common: 81% on 3.6 mg and 90% on 6.0 mg in SYNCHRONIZE-1, against 48% on placebo, mostly mild to moderate.
- In the diabetes trial, 18% of people on survodutide stopped because of them, against 1.2% on placebo.
Legal status
Survodutide is not approved for any use. The FDA has named it among the drugs it has warned research-chemical sellers about.
Common questions
Is survodutide approved?
No. As of November 2026 it is not approved for any use in any country.
How much weight did people lose on survodutide?
In SYNCHRONIZE-1, average weight loss over 76 weeks was 12.2% on 3.6 mg and 13.0% on 6.0 mg, against 5.4% on placebo.
What are the side effects of survodutide?
Stomach and gut side effects were very common: 81% on 3.6 mg and 90% on 6.0 mg in SYNCHRONIZE-1, against 48% on placebo, mostly mild to moderate.
Added in the latest update. These answers summarize the sections above; sources are listed below.
Ask an AI about this page
Opens the assistant with a question about this page already typed in. You can edit it before sending.
Ask ChatGPTAsk ClaudeAsk Perplexity
These are outside services. Amino Desk does not control or review their answers, and an AI summary is not medical advice. Check anything important against the sources below.